Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

Fitzner, Julia; Coulibaly, Daouda; Kouadio, Daniel Ekra; Yavo, J. C.; Loukou, Yao Guillaume; Koudou, Paul Odehouri; Coulombier, D

doi:10.1016/j.vaccine.2004.05.018

Cited by 30 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To better measure these differences, the average SAE rates from studies in only endemic regions [64–67] were compared to those from only non-endemic regions ([62,68,69] and unpublished US VAERS analysis in [11]). For endemic areas, a total of 234 SAEs were identified among approximately 43 million doses of YFV-17D, equaling 5.4 SAEs per million.…”

Section: Rates Of Yfv-17d Serious Adverse Events (Saes)mentioning

confidence: 99%

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Amanna

Slifka

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas Covered We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert Commentary Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

show abstract

Section: Rates Of Yfv-17d Serious Adverse Events (Saes)mentioning

confidence: 99%

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Amanna

Slifka

2016

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Even though our team and other investigators in Africa [ 25 ] did not find serious adverse events following yellow fever immunisation, AEFIs have recently become a big issue in South America and non-endemic countries where travellers are immunized against yellow fever [ 26 , 27 ]. In the early years of yellow fever vaccine production, post-vaccination encephalitis was common but such events were markedly reduced after the adoption of seed lot manufacturing in 1941 and the restriction of vaccination to persons older than six months of age after 1969 [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Yellow fever control in Cameroon: Where are we now and where are we going?

Wiysonge

Nomo

Mawo

et al. 2008

BMC Med

View full text Add to dashboard Cite

Background: Cameroon is one of 12 African countries that bear most of the global burden of yellow fever. In 2002 the country developed a five-year strategic plan for yellow fever control, which included strategies for prevention as well as rapid detection and response to outbreaks when they occur. We have used data collected by the national Expanded Programme on Immunisation to assess the progress made and challenges faced during the first four years of implementing the plan.

show abstract

“…Likewise, Fitzner et.al. reported a total of 87 minor adverse events from 2 million vaccine receivers (0.004%) [20]. Fernandez et.al.…”

Section: Demographic Parameters Vaccinated Travellersmentioning

confidence: 99%

Evaluation of Safety Profile of Yellow Fever Vaccine in Healthy Indian Travellers: A Prospective Observational Study

Tiwari¹

2015

J Pharma Care Health Sys

View full text Add to dashboard Cite

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

Cited by 30 publications

References 18 publications

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Questions regarding the safety and duration of immunity following live yellow fever vaccination

Yellow fever control in Cameroon: Where are we now and where are we going?

Evaluation of Safety Profile of Yellow Fever Vaccine in Healthy Indian Travellers: A Prospective Observational Study

Contact Info

Product

Resources

About